ITPKB and anemia (phenotype): Any therapeutic approach would also need to avoid the CVID, BM failure/anemia, and possibly neutrophil hyperactivity found in human patients or mice with persistent Itpkb lof (22, 23, 26, 57, 158), and the disruption of possible Itpkb tumor-suppressor functions discussed in the B cell section.